Search results for "Epigenetics"

showing 10 items of 517 documents

DeepWAS: Multivariate genotype-phenotype associations by directly integrating regulatory information using deep learning

2020

Genome-wide association studies (GWAS) identify genetic variants associated with traits or diseases. GWAS never directly link variants to regulatory mechanisms. Instead, the functional annotation of variants is typically inferred by post hoc analyses. A specific class of deep learning-based methods allows for the prediction of regulatory effects per variant on several cell type-specific chromatin features. We here describe “DeepWAS”, a new approach that integrates these regulatory effect predictions of single variants into a multivariate GWAS setting. Thereby, single variants associated with a trait or disease are directly coupled to their impact on a chromatin feature in a cell type. Up to…

0301 basic medicineMultivariate analysisGene ExpressionGenome-wide association studyBiochemistry0302 clinical medicineGenotypeMedicine and Health SciencesBiology (General)0303 health sciencesDNA methylationEcologyChromosome BiologyNeurodegenerative DiseasesGenomicsChromatinChromatinNucleic acidsNeurologyComputational Theory and MathematicsModeling and SimulationDNA methylationTraitEpigeneticsDNA modificationFunction and Dysfunction of the Nervous SystemChromatin modificationResearch ArticleMultiple SclerosisQH301-705.5Quantitative Trait LociImmunologySingle-nucleotide polymorphismComputational biologyBiologyQuantitative trait locusPolymorphism Single NucleotideAutoimmune DiseasesMolecular Genetics03 medical and health sciencesCellular and Molecular NeuroscienceDeep LearningGenome-Wide Association StudiesGeneticsHumansGeneMolecular BiologyGenetic Association StudiesEcology Evolution Behavior and Systematics030304 developmental biologyGenetic associationBiology and Life SciencesComputational BiologyHuman GeneticsCell BiologyDNAGenome AnalysisDemyelinating Disorders030104 developmental biologyGenetic LociMultivariate AnalysisClinical ImmunologyClinical Medicine030217 neurology & neurosurgeryGenome-Wide Association StudyPLOS Computational Biology
researchProduct

Influence of middle-distance running on muscular micro RNAs

2018

A specific subset of micro RNAs (miRs), including miR-133 and miR-206, is specifically expressed in muscle tissue, so that they are currently defined as muscular miRs (myomiRs). To further elucidate the role of myomiRs in muscle biology, we measured miR-133a and miR-206 in plasma of 28 middle-age recreational athletes. The study population consisted of 28 middle aged, recreation athletes (11 women and 17 men; mean age, 46 years) who completed a 21.1 km, half-marathon. The plasma concentration of miR-133a and miR-206, the serum concentration of creatine kinase (CK) and high-sensitivity (HS) cardiac troponin T (cTnT), as well as capillary lactate, were measured before and immediately after th…

0301 basic medicineMuscle tissueMalemedicine.medical_specialtyClinical BiochemistryRunning03 medical and health sciencesTroponin complexDistance runningTroponin TInternal medicinemedicineHumansLactic AcidMuscle SkeletalCreatine KinasemiRNAProlonged exercisebiologyepigeneticsexercisemicroRNAepigenetics; exercise; microRNA; miRNA; Running; sport; Athletes; Creatine Kinase; Female; Gene Expression Regulation; Humans; Lactic Acid; Male; MicroRNAs; Middle Aged; Multivariate Analysis; Muscle Skeletal; Physical Endurance; Running; Troponin TGeneral MedicineSkeletalrunning; epigenetics; exercise; miRNA; microRNA; sportMiddle AgedRunning timeMicroRNAs030104 developmental biologyEndocrinologymedicine.anatomical_structureGene Expression RegulationBiological significanceAthletesMultivariate Analysisbiology.proteinPhysical EndurancePopulation studyMuscleCreatine kinaseFemalesport
researchProduct

Myelin changes in Alexander disease

2018

Introduction: Alexander disease (AxD) is a type of leukodystrophy. Its pathological basis, along with myelin loss, is the appearance of Rosenthal bodies, which are cytoplasmic inclusions in astrocytes. Mutations in the gene coding for glial fibrillary acidic protein (GFAP) have been identified as a genetic basis for AxD. However, the mechanism by which these variants produce the disease is not understood. Development: The most widespread hypothesis is that AxD develops when a gain-of-function mutation causes an increase in GFAP. However, this mechanism does not explain myelin loss, given that experimental models in which GFAP expression is normal or mutated do not exhibit myelin disorders. …

0301 basic medicineMutationGlial fibrillary acidic proteinbiologyMechanism (biology)Cytoplasmic inclusionLeukodystrophymedicine.diseasemedicine.disease_causelcsh:RC346-429Alexander diseaseCell biology03 medical and health sciencesMyelin030104 developmental biology0302 clinical medicinemedicine.anatomical_structurenervous systembiology.proteinmedicineEpigeneticslcsh:Neurology. Diseases of the nervous system030217 neurology & neurosurgeryNeurología (English Edition)
researchProduct

Approaching Sex Differences in Cardiovascular Non-Coding RNA Research

2020

International audience; Cardiovascular disease (CVD) is the biggest cause of sickness and mortality worldwide in both males and females. Clinical statistics demonstrate clear sex differences in risk, prevalence, mortality rates, and response to treatment for different entities of CVD. The reason for this remains poorly understood. Non-coding RNAs (ncRNAs) are emerging as key mediators and biomarkers of CVD. Similarly, current knowledge on differential regulation, expression, and pathology-associated function of ncRNAs between sexes is minimal. Here, we provide a state-of-the-art overview of what is known on sex differences in ncRNA research in CVD as well as discussing the contributing biol…

0301 basic medicineNcRNAER-BETARNA Untranslatedexperimental modelsreceptorsReviewDisease030204 cardiovascular system & hematologyBioinformaticsCardiovascular Systemlcsh:Chemistry0302 clinical medicineSex hormone-binding globulinlncRNAestrogenMedicinePROMOTER METHYLATIONlcsh:QH301-705.5DNA METHYLATIONSpectroscopyGENE-EXPRESSIONSex CharacteristicsbiologyMortality rateGeneral MedicineMOUSE MODELNon-coding RNA[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system3. Good healthComputer Science ApplicationsHEART-FAILUREESTROGEN-RECEPTOR-ALPHAandrogenvascular cells.vascular cellsCatalysisMICRORNA THERAPEUTICSInorganic Chemistry03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmicroRNAAnimalsHumansEpigeneticsPhysical and Theoretical ChemistryX-INACTIVATIONMolecular BiologySocioeconomic statusmiRNAbusiness.industryOrganic ChemistryPOSTMENOPAUSAL HORMONE-THERAPYcardiovascular diseasesSexual dimorphism030104 developmental biologylcsh:Biology (General)lcsh:QD1-999biology.proteinbusinessBiomarkersInternational journal of molecular sciences
researchProduct

Alignment Free Dissimilarities for Nucleosome Classification

2016

Epigenetic mechanisms such as nucleosome positioning, histone modifications and DNA methylation play an important role in the regulation of cell type-specific gene activities, yet how epigenetic patterns are established and maintained remains poorly understood. Recent studies have shown a role of DNA sequences in recruitment of epigenetic regulators. For this reason, the use of more suitable similarities or dissimilarity between DNA sequences could help in the context of epigenetic studies. In particular, alignment-free dissimilarities have already been successfully applied to identify distinct sequence features that are associated with epigenetic patterns and to predict epigenomic profiles…

0301 basic medicineNearest neighbour classifiersKnn classifierSettore INF/01 - Informatica030102 biochemistry & molecular biologybiologyComputer scienceSpeech recognitionEpigeneticContext (language use)Computational biologyL-tuples03 medical and health sciences030104 developmental biologyHistoneSimilarity (network science)DNA methylationbiology.proteinNucleosomeEpigeneticsAlignment free DNA sequence dissimilaritiesk-mersNucleosome classificationEpigenomics
researchProduct

Association between DNA methylation and ADHD symptoms from birth to school age: a prospective meta-analysis

2020

Funder: Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada); doi: https://doi.org/10.13039/501100000024

0301 basic medicineOncology3124 Neurology and psychiatryEpigenesis GeneticACTIVATION0302 clinical medicine3123 Gynaecology and paediatricsPregnancyProspective StudiesProspective cohort studyChildRISK0303 health sciencesSchoolsATTENTION-DEFICIT/HYPERACTIVITY DISORDERMethylation3. Good healthPsychiatry and Mental healthMeta-analysisChild PreschoolDNA methylation/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingBiomarker (medicine)FemalePACKAGEmedicine.medical_specialtyAdolescent515 PsychologyArticlelcsh:RC321-571Cellular and Molecular Neuroscience03 medical and health sciencesSDG 3 - Good Health and Well-beingInternal medicinemedicineGeneticsAttention deficit hyperactivity disorderHumansEpigeneticslcsh:Neurosciences. Biological psychiatry. NeuropsychiatryBiological Psychiatry030304 developmental biologyGenetic associationPregnancybusiness.industryInfant NewbornPERFORMANCEDNA Methylationmedicine.diseaseGENE030104 developmental biologyAttention Deficit Disorder with HyperactivityCOHORT PROFILEEtiologybusinessPsychiatric disorders030217 neurology & neurosurgery
researchProduct

Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives

2017

Carcinosarcomas (CS) in gynecology are very infrequent and represent only 2–5% of uterine cancers. Despite surgical cytoreduction and subsequent chemotherapy being the primary treatment for uterine CS, the overall five-year survival rate is 30 ± 9% and recurrence is extremely common (50–80%). Due to the poor prognosis of CS, new strategies have been developed in the last few decades, targeting known dysfunctional molecular pathways for immunotherapy. In this paper, we aimed to gather the available evidence on the latest therapies for the treatment of CS. We performed a systematic review using the terms “uterine carcinosarcoma”, “uterine Malignant Mixed Müllerian Tumors”, “target therapies”,…

0301 basic medicineOncologyPathologyAngiogenesisCarcinosarcomas epigenetics genetics immunotherapy uterine cancer.medicine.medical_treatmentReviewEpigenesis Geneticlcsh:Chemistry0302 clinical medicineCarcinosarcomaAntibodies BispecificCarcinosarcomas Epigenetics Genetics Immunotherapy Uterine cancerMedicinegeneticsMolecular Targeted Therapylcsh:QH301-705.5Human Epidermal Growth Factor Receptor 2SpectroscopyNeovascularization PathologicGeneral MedicineEpithelial Cell Adhesion MoleculePrognosisComputer Science ApplicationsErbB ReceptorsSurvival Rate030220 oncology & carcinogenesisUterine NeoplasmsFemaleImmunotherapymedicine.medical_specialtyPoor prognosisMixed Tumor MullerianCatalysisuterine cancerInorganic Chemistry03 medical and health sciencesCancer stem cellInternal medicineBiomarkers TumorHumansTarget therapyPhysical and Theoretical ChemistrycarcinosarcomasMolecular BiologySurvival rateChemotherapyepigeneticsbusiness.industryOrganic ChemistryImmunotherapy030104 developmental biologylcsh:Biology (General)lcsh:QD1-999businessInternational Journal of Molecular Sciences
researchProduct

Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study

2016

Background & Aims No established therapies for patients with hepatocellular carcinoma (HCC) and progression on first-line sorafenib treatment currently exist. This phase I/II trial investigated safety, pharmacokinetics and potential biomarkers of the histone deacetylase inhibitor resminostat and a combination therapy with resminostat and sorafenib. Methods Patients with HCC and radiologically confirmed progression on sorafenib were treated in an exploratory, multi-center, open-label, uncontrolled, non-randomized, parallel group phase I/II study. In the combination group (n=38) four dose levels ranged from daily 200 to 600mg resminostat plus 400 to 800mg sorafenib. The monotherapy group (n=1…

0301 basic medicineOncologySorafenibmedicine.medical_specialtyCombination therapymedicine.drug_classMedizinCancer epigeneticPharmacology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineCancer epigeneticsResminostatInternal medicineClinical endpointmedicineCarcinomaneoplasmsEpigenetic treatmentFirst-in-man studyHistone deacetylase inhibitorHepatologybusiness.industryHistone deacetylase inhibitormedicine.diseasedigestive system diseases030104 developmental biologyZinc finger protein 64chemistryCancer epigenetics; Drug resistance; Epigenetic treatment; Histone deacetylase inhibitor; Zinc finger protein 64030220 oncology & carcinogenesisHepatocellular carcinomaDrug resistancebusinessmedicine.drug
researchProduct

Current molecular and clinical insights into uveal melanoma (Review)

2021

Uveal melanoma (UM) represents the most prominent primary eye cancer in adults. With an incidence of approximately 5 cases per million individuals annually in the United States, UM could be considered a relatively rare cancer. The 90.95% of UM cases arise from the choroid. Diagnosis is based mainly on a clinical examination and ancillary tests, with ocular ultrasonography being of greatest value. Differential diagnosis can prove challenging in the case of indeterminate choroidal lesions and, sometimes, monitoring for documented growth may be the proper approach. Fine needle aspiration biopsy tends to be performed with a prognostic purpose, often in combination with radiotherapy. Gene expres…

0301 basic medicineOncologyUveal NeoplasmsCancer Researchmedicine.medical_specialtydiagnosisEnucleationBiology03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansNeoplasm MetastasisGrading (tumors)MelanomaBiomarkers; Diagnosis; Epigenetics; Prognosis; Staging; Treatment; Uveal melanomamedicine.diagnostic_testtreatmentepigeneticsMelanomaGene Expression ProfilingCancerbiomarkersArticlesstagingmedicine.diseasePrognosisPrimary tumor030104 developmental biologyFine-needle aspirationOncology030220 oncology & carcinogenesisMutationDifferential diagnosisuveal melanomaGNAQ
researchProduct

Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence…

2021

The introduction of checkpoint inhibitors (ICIs) in renal cell carcinoma (RCC) treatment landscape, resulted in improvements in overall survival (OS) in metastatic patients. Brain metastases (BMs) are a specific metastatic site of interest representing a predictive factor of poor prognosis. Patients with BMs were usually excluded from prospective clinical trials in the past. Despite recent evidence suggest the efficacy and safety of ICIs, the BMs treatment remains a challenge; the immunotherapy responsiveness seems to be multifactorial and dependent on several factors, such as the genetic intratumor heterogeneity and the immunosuppressive role of the brain tumor microenvironment. This revie…

0301 basic medicineOncologymedicine.medical_specialtySettore MED/06 - Oncologia MedicaImmune checkpoint inhibitorsmedicine.medical_treatmentImmune-checkpoint inhibitorsBrain tumorEpigenetic remodeling03 medical and health sciences0302 clinical medicineImmune systemRenal cell carcinomaInternal medicineTumor MicroenvironmentHumansMedicineProspective StudiesEpigeneticsCarcinoma Renal CellImmune Checkpoint InhibitorsBrain Neoplasmsbusiness.industrySettore MED/37 - NeuroradiologiaCancerBrain metastasesHematologyImmunotherapymedicine.diseaseKidney NeoplasmsRenal cell carcinomaClinical trialRenal cancer030104 developmental biologyOncology030220 oncology & carcinogenesisImmunotherapySettore MED/36 - Diagnostica Per Immagini E RadioterapiabusinessBrain tumor microenvironmentNeuroradiological response evaluationCritical Reviews in Oncology/Hematology
researchProduct